Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial
Alice Tsang Shaw, Tae Min Kim, Lucio Crinò et al. · The Lancet Oncology · 2017
Cited by 567 works. doi:10.1016/s1470-2045(17)30339-x
Authors
- Alice Tsang Shaw
- Tae Min Kim
- Lucio Crinò
- Cesare Gridelli
- Katsuyuki Kiura
- Geoffrey Liu
- Silvia Novello
- Alessandra Bearz
- Oliver Pascal Gautschi
- Tony S.K. Mok
- Makoto Nishio
- Giorgio V. Scagliotti
- David Robert Spigel
- Stéphanie Deudon
- Cheng Chao Zheng
- Serafino Pantano
- Patrick Urban
- Cristian Massacesi
- Kalyanee Viraswami-Appanna
- Enriqueta Felip
References
- Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
- Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial
- A Confidence Interval for the Median Survival Time
- Crizotinib versus Chemotherapy in Advanced ALK -Positive Lung Cancer
- First-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
- Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study
- Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers
- Mechanisms of Resistance to Crizotinib in Patients with ALK Gene Rearranged Non–Small Cell Lung Cancer
- Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis
- First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study